Total Payments
$33,264
2024 Payments
$3,760
Companies
40
Transactions
1,932
Medicare Patients
12,336
Medicare Billing
$9.7M
Payment Breakdown by Category
Food & Beverage$29,866 (89.8%)
Consulting$2,939 (8.8%)
Education$458.48 (1.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $29,866 | 1,919 | 89.8% |
| Consulting Fee | $2,939 | 6 | 8.8% |
| Education | $458.48 | 7 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $5,442 | 293 | $0 (2024) |
| ABBVIE INC. | $4,958 | 274 | $0 (2024) |
| Janssen Biotech, Inc. | $3,514 | 198 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $3,097 | 16 | $0 (2018) |
| PFIZER INC. | $2,592 | 259 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,218 | 131 | $0 (2024) |
| UCB, Inc. | $1,646 | 106 | $0 (2024) |
| Lilly USA, LLC | $1,362 | 110 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,060 | 77 | $0 (2024) |
| Genentech USA, Inc. | $1,009 | 68 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,760 | 174 | Amgen Inc. ($1,158) |
| 2023 | $4,367 | 214 | ABBVIE INC. ($955.31) |
| 2022 | $3,620 | 214 | ABBVIE INC. ($709.44) |
| 2021 | $3,724 | 250 | Amgen Inc. ($693.11) |
| 2020 | $2,968 | 219 | Amgen Inc. ($703.37) |
| 2019 | $4,315 | 312 | Amgen Inc. ($807.22) |
| 2018 | $7,081 | 301 | Ironwood Pharmaceuticals, Inc ($3,019) |
| 2017 | $3,428 | 248 | AbbVie, Inc. ($492.08) |
All Payment Transactions
1,932 individual payment records from CMS Open Payments — Page 1 of 78
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Immunology | ||||||
| 12/11/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Inflammation | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: Immunology | ||||||
| 11/27/2024 | SOBI, INC | KINERET (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Immunology | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $25.20 | General |
| Category: Immunology | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $106.75 | General |
| Category: Inflammation | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $123.59 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Not Applicable | ||||||
| 11/07/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: Inflammation | ||||||
| 11/06/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Inflammation | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Dermatology | ||||||
| 11/05/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Analgesic | ||||||
| 11/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $34.98 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/29/2024 | ABBVIE INC. | HUMIRA (Biological), RINVOQ | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: LUPUS NEPHRITIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 2,191 | 140,120 | $4.9M | $2.0M |
| 2022 | 29 | 2,870 | 144,729 | $5.1M | $2.1M |
| 2021 | 31 | 3,283 | 140,321 | $5.6M | $2.5M |
| 2020 | 37 | 3,992 | 152,983 | $6.3M | $3.1M |
Total Patients
12,336
Total Services
578,153
Medicare Billing
$9.7M
Procedure Codes
123
All Medicare Procedures & Services
123 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 35 | 24,000 | $1.6M | $808,978 | 51.9% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 45 | 38,227 | $1.3M | $389,812 | 29.1% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 15 | 63,890 | $638,900 | $293,223 | 45.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 591 | 1,812 | $322,536 | $149,046 | 46.2% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 18 | 4,230 | $528,750 | $111,638 | 21.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 46 | 4,620 | $138,600 | $85,283 | 61.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 111 | 582 | $107,670 | $26,749 | 24.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 217 | 345 | $51,750 | $19,839 | 38.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 44 | 179 | $42,065 | $15,693 | 37.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 74 | 124 | $27,900 | $14,936 | 53.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 90 | 90 | $28,800 | $12,533 | 43.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 289 | 860 | $8,600 | $7,124 | 82.8% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 118 | 237 | $25,359 | $3,411 | 13.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 24 | 154 | $18,480 | $3,197 | 17.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 55 | 55 | $3,410 | $1,931 | 56.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $3,750 | $1,753 | 46.7% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 37 | 73 | $5,840 | $1,387 | 23.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 25 | 30 | $5,400 | $1,367 | 25.3% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 77 | 77 | $6,776 | $1,214 | 17.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 34 | 170 | $8,500 | $1,113 | 13.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 63 | 94 | $6,110 | $950.16 | 15.6% |
| 73620 | X-ray of foot, 2 views | Office | 2023 | 28 | 55 | $5,060 | $754.85 | 14.9% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 55 | 84 | $1,260 | $474.98 | 37.7% |
| 73502 | X-ray of hip, 2-3 views | Office | 2023 | 11 | 13 | $1,196 | $316.68 | 26.5% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 28 | 55 | $2,475 | $215.38 | 8.7% |
About Dr. Christopher Morris, MD
Dr. Christopher Morris, MD is a Rheumatology healthcare provider based in Kingsport, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295831733.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Morris, MD has received a total of $33,264 in payments from pharmaceutical and medical device companies, with $3,760 received in 2024. These payments were reported across 1,932 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($29,866).
As a Medicare-enrolled provider, Morris has provided services to 12,336 Medicare beneficiaries, totaling 578,153 services with total Medicare billing of $9.7M. Data is available for 4 years (2020–2023), covering 123 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Kingsport, TN
- Active Since 09/15/2006
- Last Updated 07/21/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1295831733
Products in Payments
- Enbrel (Biological) $3,419
- DUZALLO (Drug) $3,050
- RINVOQ (Biological) $2,516
- XELJANZ (Drug) $2,229
- COSENTYX (Biological) $1,775
- TREMFYA (Drug) $1,770
- Cimzia (Drug) $1,560
- TALTZ (Drug) $1,175
- SIMPONI ARIA (Biological) $1,152
- Humira (Biological) $1,083
- BENLYSTA (Biological) $1,053
- ORENCIA (Biological) $871.35
- Rituxan (Biological) $762.47
- KRYSTEXXA (Biological) $723.42
- ACTHAR (Biological) $633.68
- EVENITY (Biological) $558.92
- REMICADE (Biological) $542.22
- LUPKYNIS (Drug) $453.90
- SAPHNELO (Biological) $444.54
- KEVZARA (Biological) $425.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.